Literature DB >> 20203200

Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.

Elpida Tsika1, Maria Moysidou, Jing Guo, Mimi Cushman, Patrick Gannon, Raphael Sandaltzopoulos, Benoit I Giasson, Dimitri Krainc, Harry Ischiropoulos, Joseph R Mazzulli.   

Abstract

Aggregation of alpha-synuclein (alpha-syn), a process that generates oligomeric intermediates, is a common pathological feature of several neurodegenerative disorders. Despite the potential importance of the oligomeric alpha-syn intermediates in neuron function, their biochemical properties and pathobiological functions in vivo remain vastly unknown. Here we used two-dimensional analytical separation and an array of biochemical and cell-based assays to characterize alpha-syn oligomers that are present in the nervous system of A53T alpha-syn transgenic mice. The most prominent species identified were 53 A detergent-soluble oligomers, which preceded neurological symptom onset, and were found at equivalent amounts in regions containing alpha-syn inclusions as well as histologically unaffected regions. These oligomers were resistant to SDS, heat, and urea but were sensitive to proteinase-K digestion. Although the oligomers shared similar basic biochemical properties, those obtained from inclusion-bearing regions were prominently reactive to antibodies that recognize oxidized alpha-syn oligomers, significantly accelerated aggregation of alpha-syn in vitro, and caused primary cortical neuron degeneration. In contrast, oligomers obtained from non-inclusion-bearing regions were not toxic and delayed the in vitro formation of alpha-syn fibrils. These data indicate that specific conformations of alpha-syn oligomers are present in distinct brain regions of A53T alpha-syn transgenic mice. The contribution of these oligomers to the development of neuron dysfunction appears to be independent of their absolute quantities and basic biochemical properties but is dictated by the composition and conformation of the intermediates as well as unrecognized brain-region-specific intrinsic factors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20203200      PMCID: PMC2844128          DOI: 10.1523/JNEUROSCI.4977-09.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  55 in total

1.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Authors:  Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

2.  Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis.

Authors:  Sampathkumar Krishnan; Eva Y Chi; Stephen J Wood; Brent S Kendrick; Cynthia Li; William Garzon-Rodriguez; Jette Wypych; Theodore W Randolph; Linda O Narhi; Anja Leona Biere; Martin Citron; John F Carpenter
Journal:  Biochemistry       Date:  2003-01-28       Impact factor: 3.162

3.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

Review 4.  Alpha-synuclein: normal function and role in neurodegenerative diseases.

Authors:  Erin H Norris; Benoit I Giasson; Virginia M-Y Lee
Journal:  Curr Top Dev Biol       Date:  2004       Impact factor: 4.897

5.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal.

Authors:  L Maroteaux; J T Campanelli; R H Scheller
Journal:  J Neurosci       Date:  1988-08       Impact factor: 6.167

6.  Deficits in feeding behavior after intraventricular injection of 6-hydroxydopamine in rats.

Authors:  M J Zigmond; E M Stricker
Journal:  Science       Date:  1972-09-29       Impact factor: 47.728

7.  Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein.

Authors:  Deborah E Cabin; Kazuhiro Shimazu; Diane Murphy; Nelson B Cole; Wolfram Gottschalk; Kellie L McIlwain; Bonnie Orrison; Amy Chen; Christopher E Ellis; Richard Paylor; Bai Lu; Robert L Nussbaum
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

8.  Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease.

Authors:  Jie Li; Min Zhu; Amy B Manning-Bog; Donato A Di Monte; Anthony L Fink
Journal:  FASEB J       Date:  2004-04-01       Impact factor: 5.191

9.  Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.

Authors:  Michael K Lee; Wanda Stirling; Yanqun Xu; Xueying Xu; Dike Qui; Allen S Mandir; Ted M Dawson; Neal G Copeland; Nancy A Jenkins; Don L Price
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

10.  Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.

Authors:  Benoit I Giasson; John E Duda; Shawn M Quinn; Bin Zhang; John Q Trojanowski; Virginia M-Y Lee
Journal:  Neuron       Date:  2002-05-16       Impact factor: 17.173

View more
  50 in total

Review 1.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

Review 2.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

Review 3.  Dynamic structural flexibility of α-synuclein.

Authors:  Danielle E Mor; Scott E Ugras; Malcolm J Daniels; Harry Ischiropoulos
Journal:  Neurobiol Dis       Date:  2015-12-31       Impact factor: 5.996

Review 4.  The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration.

Authors:  Danielle E Mor; Malcolm J Daniels; Harry Ischiropoulos
Journal:  Mov Disord       Date:  2019-01-11       Impact factor: 10.338

5.  Regional deficiencies in chaperone-mediated autophagy underlie α-synuclein aggregation and neurodegeneration.

Authors:  Kristen A Malkus; Harry Ischiropoulos
Journal:  Neurobiol Dis       Date:  2012-03-09       Impact factor: 5.996

6.  Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  J Neurosci       Date:  2012-10-24       Impact factor: 6.167

7.  Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.

Authors:  Joseph R Mazzulli; You-Hai Xu; Ying Sun; Adam L Knight; Pamela J McLean; Guy A Caldwell; Ellen Sidransky; Gregory A Grabowski; Dimitri Krainc
Journal:  Cell       Date:  2011-06-23       Impact factor: 41.582

Review 8.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

9.  E46K α-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation.

Authors:  Ignacio Íñigo-Marco; Miguel Valencia; Laura Larrea; Ricardo Bugallo; Mikel Martínez-Goikoetxea; Iker Zuriguel; Montserrat Arrasate
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-12       Impact factor: 11.205

10.  Transmission of Soluble and Insoluble α-Synuclein to Mice.

Authors:  Daryl Rhys Jones; Marion Delenclos; AnnMarie T Baine; Michael DeTure; Melissa E Murray; Dennis W Dickson; Pamela J McLean
Journal:  J Neuropathol Exp Neurol       Date:  2015-12       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.